Go Pro
→ Your 401(k) May Not Be Ready for This (From Priority Gold) (Ad)tc pixel
NASDAQ:NXTC

NextCure Q2 2026 Earnings Report

NextCure logo
$6.62 +0.78 (+13.36%)
As of 03:57 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

NextCure EPS Results

Actual EPS
-$2.80
Consensus EPS
-$1.95
Beat/Miss
Missed by -$0.85
One Year Ago EPS
N/A

NextCure Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

NextCure Announcement Details

Quarter
Q2 2026
Date
8/6/2026
Time
After Market Closes
Conference Call Date
Thursday, August 6, 2026
Conference Call Time
4:00PM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

NextCure's Q2 2026 Press ReleasePress Release
(8-K)
NextCure's Q2 2026 Quarterly reportQuarterly report
(10-Q)

NextCure Earnings Headlines

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001
August 10 at 7:00 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/avere-therapeutics-announces-500-million-private-placement-to-support-development-of-once-weekly-oral-il-23-therapy-avr-001-302846694.html
NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results
August 6, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/nextcure-provides-business-update-and-reports-second-quarter-2026-financial-results-1036422678
AI Is Coming for Your Money
An AI model recently broke into a company on its own, with no instructions given. The incident raises a bigger question: what exactly do you own when your money is digital. Most of the American money supply is not paper cash, it is data on servers protected by a single password and network. See the three moves that could put part of your retirement out of reach from digital threats.tc pixel
August 10 at 1:00 AM  |  Priority Gold (Ad)
NextCure (NASDAQ:NXTC) Major Shareholder Adar1 Capital Management, Llc Buys 292,850 Shares of Stock
August 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30940719
The M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—VEEE, NXTC, TCBK, and FHB
July 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/23/3332390/0/en/the-m-a-class-action-firm-encourages-hareholders-to-contact-monteverde-concerning-the-merger-veee-nxtc-tcbk-and-fhb.html
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—VEEE, NXTC, TCBX, and FHB
July 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/21/3330721/0/en/hareholder-alert-the-m-a-class-action-firm-launches-legal-inquiry-for-the-merger-veee-nxtc-tcbx-and-fhb.html
See More NextCure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NextCure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NextCure and other key companies, straight to your email.

About NextCure

NextCure (NASDAQ:NXTC) is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation. Lead programs such as NX-1607, an oral small molecule inhibitor targeting the CD200 checkpoint, and NX-0255, a monoclonal antibody directed against KIR3DL2, are being developed for solid tumors and hematologic malignancies. NextCure is also advancing NX-5948, an oral Bruton’s tyrosine kinase (BTK) degrader, into studies for B-cell malignancies. Strategic partnerships with global pharmaceutical companies support NextCure’s efforts to expand its research capabilities and accelerate clinical programs across oncology and immunology indications.

Founded in 2013 and headquartered in Beltsville, Maryland, NextCure operates state‐of‐the‐art research and development facilities in the greater Washington, D.C. area. The company conducts clinical trials across North America and Europe, collaborating with leading academic institutions and healthcare centers. By combining novel target discovery with rigorous translational and clinical research, NextCure seeks to bring new immunotherapeutic options to patients worldwide.

View NextCure Profile
Earnings Tools